Semaglutide

Sublingual

2.5 mg/mL

Ready to prescribe?

Disclaimer: Images are for reference only; actual products may vary.

Product Overview Coming Soon

Product Overview

Product Description

Semaglutide Description^1-6

Semaglutide is a synthetic glucagon-like peptide-1 receptor agonist (GLP-1 RA) that functions as an incretin mimetic. Incretins are hormones released from the gastrointestinal tract into the systemic circulation that support glycemic control and have been utilized in weight management. When administered orally, semaglutide is indicated for the following use:

Treatment of type 2 diabetes mellitus as an adjunct to diet and exercise

Data indicate that oral semaglutide may produce clinically meaningful outcomes for individuals seeking weight reduction. In a 68-week study, oral semaglutide was associated with an average weight decrease of approximately 15%.

References

Semaglutide (Ozempic) Prescribing Information – Novo Nordisk https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209637lbl.pdf. Revised December 2017. Accessed May 27, 2025
Semaglutide (Wegovy) Prescribing Information Novo Nordisk www.accessdata.fda.gov/drugsatfda_docs/label/2023/215256s007lbl.pdf. Revised July 2023. Accessed June 22, 2025
Semaglutide (Rybelsus) Prescribing Information https://www.novo-pi.com/rybelsus.pdf December 2024. Accessed June 22, 2025
Clinical Pharmacology semaglutide clinical monograph 2025 https://www.clinicalkey.com/pharmacology/
Knudsen LB, Lau J. The Discovery and Development of Liraglutide and Semaglutide. Front Endocrinol (Lausanne). 2019 Apr 12;10:155.
Knop FK, Aroda VR, do Vale RD, Holst-Hansen T, Laursen PN, Rosenstock J, Rubino DM, Garvey WT; OASIS 1 Investigators. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023 Aug 26;402(10403):705-719.

Product Mechanism of Action

Mechanism of Action^1-6

Semaglutide is an incretin mimetic that works on the glucagon-like peptide-1 (GLP-1) receptor by binding and activating the GLP-1 receptor. It has 94% sequence homology to human GLP-1. GLP-1 medications regulate glucose metabolism after oral consumption of carbohydrates and fats. The drug increases insulin secretion by glucose-dependent insulin synthesis and in vivo secretion of insulin from pancreatic beta cells in the presence of elevated glucose. It also suppresses glucagon secretion, slows gastric emptying, reduces food intake, and promotes beta-cell proliferation.

Product Adverse Reactions

Common^3,4

Gastrointestinal: Nausea, vomiting, diarrhea, constipation, dyspepsia.
Headache, dizziness, and injection site reactions.

Product Contraindications & Precautions

Contraindications^3,4

Hypersensitivity to liraglutide or its components
In people with a personal or family history of medullary thyroid carcinoma (MTC) or in people with multiple endocrine neoplasia syndrome type 2
In patients who are pregnant

Precautions^3,4

In patients with a history of pancreatitis and gall bladder disease
In patients with renal and hepatic impairment

Product Storage

Refrigerate at 2–8°C (36–46°F) before and during use. Do not freeze. Protect from light and excessive heat.

Product References

Semaglutide (Ozempic) Prescribing Information – Novo Nordisk https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209637lbl.pdf. Revised December 2017. Accessed May 27, 2025
Semaglutide (Wegovy) Prescribing Information Novo Nordisk www.accessdata.fda.gov/drugsatfda_docs/label/2023/215256s007lbl.pdf. Revised July 2023. Accessed June 22, 2025
Semaglutide (Rybelsus) Prescribing Information https://www.novo-pi.com/rybelsus.pdf December 2024. Accessed June 22, 2025
Clinical Pharmacology semaglutide clinical monograph 2025 https://www.clinicalkey.com/pharmacology/
Knudsen LB, Lau J. The Discovery and Development of Liraglutide and Semaglutide. Front Endocrinol (Lausanne). 2019 Apr 12;10:155.
Knop FK, Aroda VR, do Vale RD, Holst-Hansen T, Laursen PN, Rosenstock J, Rubino DM, Garvey WT; OASIS 1 Investigators. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023 Aug 26;402(10403):705-719.

Product Disclaimer

This information is for educational purposes only.

This compounded product has not been reviewed, approved, or evaluated by the Food and Drug Administration for safety and effectiveness. This product is not intended to diagnose, treat, cure, or prevent any disease. No claims are made regarding treatment, cure, or prevention of any disease or condition.

This information is a summary. It may not cover all possible drug information about this product. For complete product information, refer to the manufacturer’s prescribing information and labeling. Call your doctor for medical advice and/or about side effects. You may report side effects to the FDA at 1-800-FDA-1088. A WP Pharma Labs pharmacist will be happy to answer any questions. For consultation, please call 1-800-441-0048.

EXPLORE MORE

Related Medications

Enclomiphene Citrate

Letrozole

Testosterone Cypionate in Grapeseed Oil

Testosterone Cypionate / Enanthate

Testosterone Cypionate / DHEA

Testosterone Propionate

DHEA SR

MI / B-Complex (B2, B3, B5) / Chromium / Carnitine

Sermorelin

Tirzepatide / Glycine

Sermorelin

T3 IR or SR

Naltrexone (LDN)

Sermorelin / Theanine

Glutathione-L

Synapsin

Synapsin / B12(M) / Alpha-GPC

VIP Nasal Spray

Tretinoin / CoQ10

Licensed to ship across the U.S.

Your orders arrive promptly and privately, delivered directly to your door.

Providers: Let’s Partner for Better Patient Care

If you are a physician, clinic, or practice seeking a dependable Compounding Pharmacy partner, WP Pharma Labs is here to help. With dedicated account setup, streamlined ordering and responsive service, we support your therapeutic goals with specialized compounds designed for your patients.

To check product availability, check on the status of an existing order, request refills:
orders@wppharmalabs.com

New providers setup / update an existing account:
newaccounts@wppharmalabs.com